To order this detailed 480+ page report, please visit this -https://www.rootsanalysis.com/reports/view_document/biologics-fill--finish-services-market-2019-2030/256.html
Key Inclusions
§ A detailed assessmentof the current market landscape, including information on drug developer(s),phase of development (marketed, clinical and preclinical / discovery stage) oflead candidates, target immune checkpoints, their respective mechanisms ofaction (inhibitory or stimulatory), type of therapeutic modality used(monoclonal antibody, antibody fragment, small molecule and others), route ofadministration (intravenous, subcutaneous, oral and others), target diseaseindication, target therapeutic area and type of therapy (monotherapy,combination therapy and both).
§ A detailed analysisof more than 590 completed, ongoing and planned clinical studies of nextgeneration immune checkpoint inhibitors and stimulators, highlighting prevalenttrends across various relevant parameters, such as current trial status, trialregistration year, phase of development, study design, leading industrysponsors / collaborators (in terms of number of trials conducted), trialfocus, type of target, target indication(s), target therapeutic area(s),enrolled patients population and regional distribution.
§ Detailed profiles ofdevelopers of next generation immune checkpoint modulators (shortlisted onthe basis of the number of pipeline products), featuring an overview of thecompany, its financial information (if available), a detailed descriptionof its product portfolio and recent collaborations. In addition, each profileincludes an informed future outlook.
§ An in-depth analysisof more than 490 grants that have been awarded to research institutes engagedin next generation immune checkpoint therapy-related projects, in the periodbetween 2016 and 2019 (till November), including analysis based onimportant parameters, such as year of grant award, amount awarded,administration institute center, funding institute center, support period, typeof grant application, purpose of grant award, grant mechanism, popular targetimmune checkpoints, responsible study section, focus area, prominent programofficers, and type of recipient organizations. It also features a detailedanalysis based on the types of target immune checkpoints and therapeutic areas,along with a multivariate grant attractiveness analysis based on parameters,such as grant amount, support period, type of grant application and number ofdisease indications under investigation.
§ An analysis of thepartnerships that have been established in the recent past, covering R&Dcollaborations, licensing agreements (specific to affiliated technologyplatforms and product candidates), product development and commercializationagreements, clinical trial agreements, manufacturing agreements, mergers andacquisitions, manufacturing and service agreements, and other relevant types ofdeals.
§ An insightfulcompetitiveness analysis of biological targets, featuring a [A]three-dimensional bubble representation that highlights the targets that arebeing evaluated for next generation immune checkpoint therapy development,taking into consideration the number of lead molecules based on a particular target,phase of development of candidate therapies, number of grants and number ofpublications [B] a five-dimensional spider-web analysis, highlighting the mostpopular immune checkpoint targets.
§ An analysis of thebig biopharma players engaged in this domain, featuring a heat map based onparameters, such as number of therapies under development, target diseaseindications, partnership activity and target portfolio.
§ Informed estimates ofthe existing market size and the future opportunity for contract fill / finishservices for biologics, over the next decade. Based on multiple parameters,such as biopharmaceutical contract services market size, share of fill / finishservices and their likely outsourcing profile, we have provided informed estimateson the evolution of the market for the period 2019-2030.
The report also features the likelydistribution of the current and forecasted opportunity across important marketsegments, mentioned below:
§ Types of PrimaryPackaging Containers
§ Ampoules
§ Cartridges
§ Syringes
§ Vials
§ Types of Biologics
§ Peptides / proteins
§ Antibodies
§ Vaccines
§ Cell therapies
§ Gene therapies
§ Viral products
§ Oligonucleotides
§ Others
§ Company Size
§ Small-sized
§ Mid-sized
§ Large / very large
§ Scale of Operation
§ Preclinical
§ Clinical
§ Commercial
§ Key Therapeutic Areas
§ Cancer
§ Infectious diseases
§ Autoimmune diseases
§ Cardiovasculardiseases
§ Other indications
§ Key GeographicalRegions
§ North America (US,Canada)
§ Europe (UK, France,Germany, Italy, Spain and rest of the Europe)
§ Asia-Pacific (Japan,China, South Korea, India and Australia)
The report featuresinputs from a number of eminent industry stakeholders, according to whom,“Currently, majority of biologics are being filled in vials, however, the scenariois likely to change in the future due to the growing demand and preference forself-administration devices.” The report features detailed transcripts ofdiscussions held with the following experts:
§ Ales Sima, Business Development Manager,oncomed manufacturing
§ Gregor Kawaletz, Chief Commercial Officer,IDT Biologika
§ Jos Vergeest, International BusinessDeveloper, HALIX
§ Purushottam Singnurkar, Research Directorand Head of Formulation Development, Syngene International
To request sample pages, please visit this -https://www.rootsanalysis.com/reports/256/request-sample.html
Key Questions Answered
§ Who are the leadingindustry players engaged in the contract fill / finish services market forbiologics?
§ Which are theprominent packaging formats used for biologics?
§ Where are the playerssetting up new facilities or adding infrastructure across the globe?
§ Which partnershipmodels are commonly adopted by stakeholders in this industry?
§ What is the currentfill / finish supply?
§ What is the demandfor contract fill / finish services for biologics?
§ How is the currentand future market opportunity likely to be distributed across key marketsegments?
You may also be interested in the following titles:
1. Vaccine Contract Manufacturing Market (2nd Edition), 2019-2030
2. Medical Device Contract Manufacturing Market, 2019-2030
3. Elastomeric Closure Components Market For Vials, Cartridgesand Syringes, 2019-2030: Focus on Caps,Needle Shields, Plungers, Stoppers, Seals, Tip Caps and Other Closures
4. Biopharma Contract Manufacturing Market (3rd Edition), 2019 - 2030
5. Patient Recruitment and Retention Services Market, 2019-2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
